

A NEW METHOD FOR SYNTHESIZING THE ANTINEOPLASTIC NUCLEOSIDES 1-(2-AZIDO-2-DEOXY- β -D-ARABINOFURANOSYL)CYTOSINE (CYTARAZID) AND 1-(2-AMINO-2-DEOXY- β -D-ARABINOFURANOSYL)CYTOSINE (CYTARAMIN) FROM URIDINE¹⁾

Akira MATSUDA,* Johji YASUOKA, and Tohru UEDA

Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060, Japan

A new method was developed for synthesizing of antineoplastic nucleosides 1-(2-azido-2-deoxy- β -D-arabinofuranosyl)cytosine (**2**) and 1-(2-amino-2-deoxy- β -D-arabinofuranosyl)cytosine (**3**) from uridine. The reaction of N3-benzoyluridine derivative (**5**) with DPPA, triphenylphosphine and diethyl azodicarboxylate gave the desired 2'-azido-arabinosyl derivative (**6**), which was subsequently transformed to lead **2** and **3**.

KEYWORDS cytarazid; cytaramin; uridine; N3-benzoyluridine; diethyl azodicarboxylate; diphenylphosphorazide; intermolecular nucleophilic substitution; 1-(2-azido-2-deoxy- β -D-arabinofuranosyl)cytosine; 1-(2-amino-2-deoxy- β -D-arabinofuranosyl)cytosine

1-(2-Azido-2-deoxy- β -D-arabinofuranosyl)cytosine (**2**, cytarazid) and 1-(2-amino-2-deoxy- β -D-arabinofuranosyl)cytosine (**3**, cytaramin) have been synthesized by Bobek *et al.*^{2,3)} as analogs of 1-(β -D-arabinofuranosyl)cytosine (**1**, araC), one of the clinically useful anticancer drugs. These nucleosides are significantly antileukemic to mouse leukemia L1210, human T-cell acute lymphoblastic leukemia Molt 4F and HeLa cells *in vitro* at concentrations of 7×10^{-8} to 3×10^{-5} M. Also **2** and **3** are significantly antileukemic against L1210 *in vivo* when administrated at 40 and 75 mg/Kg, respectively, twice daily for 2 days, with over 120-day, long-term survivors. It is noteworthy that these nucleosides were resistant to cytidine deaminase, which converts araC to a chemotherapeutically inactive araU.

The original synthesis method for **2** involved a multistep synthesis of anomeric 3-O-acetyl-5-O-benzoyl-2-azido-2-deoxy-D-arabinofuranosyl chlorides from D-glucose to be condensed with a base.²⁻⁵⁾ The desired β -nucleoside was obtained in only 37% by this method, along with the formation of the α -anomer





Chart 1

(10%).⁶⁾ Therefore, further evaluation of **2** and **3** depends on the availability of these compounds. It seems worthwhile to develop a synthetic route from readily accessible pyrimidine nucleosides such as uridine or cytidine. However, it has been generally recognized that the intramolecular nucleophilic attack of the 2-carbonyl group of the uracil base on the 2' position having a leaving group in the uridine derivative is predominant rather than the intermolecular nucleophilic substitution (Chart 1). For example, treatment of TIPDS-uridine with triflic anhydride afforded the 2,2'-anhydrouridine derivative only as an isolable product.⁷⁾ Loibner and Zbiral reported that 3'-azido-3'-deoxy- β -D-xylofuranosyluracil was obtained when 2',5'-di-O-trityluridine was treated with a combination of hydrogen azide, triphenylphosphine, and diethyl azodicarboxylate, without formation of the 2,3'-anhydrouridine derivative. However, when this procedure was applied to 3',5'-di-O-trityluridine, the product was the 2,2'-anhydrouridine derivative, and 2'-azido-2'-deoxy- β -D-arabino-furanosyluracil was not obtained at all.⁸⁾ If the nucleophilicity of the 2-carbonyl oxygen could be reduced, the direct S_N2 reaction at the 2'-position of uridine would be realized. After several attempts, we found a benzoyl group as a choice of the N3-protection. In this communication we describe a new simple method for synthesizing **2** and **3** from N3-benzoyl-uridine derivative.

The starting nucleoside, 1-(3,5-tetraisopropylidisiloxan-1,3-diyl)- β -D-ribofuranosyl-N3-benzoyluracil (**5**) in 69% yield, was obtained by treating of compound (**4**) with benzoyl chloride (1.1 mol eq) in the presence of triethylamine in dichloromethane. When nucleoside **5** was treated with a mixture of hydrogen azide, triphenylphosphine and diethyl azodicarboxylate⁷⁾ in tetrahydrofuran at room temperature, the desired 2'-"up"-azidouridine derivative (**6**) was obtained in 62% yield as a foam after purification over a silica gel column. The ¹H-NMR spectrum of **6** showed a doublet (6.9 Hz) for H-1' at 6.24 ppm. This shows that the 2'-substituent is oriented to *cis* to the glycosyl linkage. Compound **6** was then deprotected to the free nucleoside, 1-(2-azido-2-deoxy- β -D-arabinofuranosyl)uracil, whose physical properties are clearly different from those of the known 1-(2-azido-2-deoxy- β -D-ribofuranosyl)uracil.⁹⁾ Thus, it is clear that the



intermolecular nucleophilic substitution of **5** by azide ion overcomes the intramolecular attack of the 2-carbonyl nucleophile by protecting the N3-position of uridine with the benzoyl group. To avoid using toxic hydrogen azide, we then examined diphenylphosphorazide (DPPA).¹⁰⁾ In the combination with DPPA, triphenylphosphine and diethyl azodicarboxylate,¹¹⁾ we obtained the best result from **5** to yield **6** in 74%. This is, to our knowledge, the first indication that the intermolecular nucleophilic substitution is superior to the intramolecular displacement of the 2-carbonyl nucleophile of uridine to the 2'-position.

Compound **6** was then treated with NH₄OH in MeOH to afford a crystalline **7** (94% yield),¹²⁾ which was a key intermediate to cytarazid and cytaramin. Compound **7** was converted to the 4-triazolide (**8**) by treatment with phosphoryl oxychloride, triethylamine and 1,2,4-triazole in acetonitrile,¹³⁾ which was then converted to the cytidine derivative (**9**) by treatment with NH₄OH. Subsequently, compound **9** was deblocked by treatment with tetrabutylammonium fluoride to give cytarazid (**2**) in 80% yield as HCl salt.¹⁴⁾ Cytarazid (**2**) was hydrogenated over Pd-carbon in HCl/MeOH to furnish cytaramin (**3**), obtained as 2HCl salt in 94% yield.¹⁵⁾

The overall yield of **2** from uridine was 33% and this method seems superior to the current condensation procedure.

REFERENCES AND NOTES

- 1) This paper constitutes Part 89 of "Nucleosides and Nucleotides"; part 88: Y. Yoshimura, A. Matsuda, and T. Ueda, *Chem. Pharm. Bull.*, **37**, 660 (1989).
- 2) M. Bobek, Y. C. Cheng, and A. Bloch, *J. Med. Chem.*, **21**, 597 (1978).
- 3) M. Bobek, Y. C. Cheng, E. Mihich, and A. Bloch, *Recent Results Cancer Res.*, **74**, 78 (1980).
- 4) M. Bobek and V. Martin, *Tetrahedron Lett.*, **22**, 1919 (1978).
- 5) M. Bobek, *Carbohydr. Res.*, **70**, 263 (1979).
- 6) M. Bobek, Y. C. Cheng, and A. Bloch, *Japan kokai* 55-500441 (1980).
- 7) K. Fukukawa, T. Ueda, and T. Hirano, *Chem. Pharm. Bull.*, **31**, 1582 (1983).
- 8) H. Loibner and E. Zbiral, *Liebigs Ann. Chem.*, **1978**, 78.
- 9) J. H. P. Verheyden, D. Wagner, and J. G. Moffatt, *J. Org. Chem.*, **36**, 250 (1971).
- 10) T. Shioiri, K. Ninomiya, and S. Yamada, *J. Am. Chem. Soc.*, **94**, 6203 (1972).
- 11) B. Lal, B. N. Pramanik, M. S. Manhas, and A. K. Bose, *Tetrahedron Lett.*, **23**, 1977 (1977).
- 12) mp 156-157°C (MeOH); ¹H-NMR (CDCl₃) δ: 1.07 (28H, m, iso-Pro), 3.83-4.32 (5H, m, 2',3',4',5',5''-H), 5.71 (1H, d, 5-H, J_{5,6} = 8.1 Hz), 6.25 (1H, d, 1'-H, J_{1',2'} = 6.1 Hz), 7.63 (1H, d, 6-H, J_{5,6} = 8.1 Hz), 8.36 (1H, brs, NH); IR(nujol) 2190 cm⁻¹.
- 13) W. L. Sung, *J. Chem. Soc., Chem. Commun.*, **1981**, 1089; *idem*, *Nucleic Acids Res.*, **9**, 6139 (1982); *idem*, *J. Org. Chem.*, **47**, 3623 (1982).
- 14) mp 165°C (eff. H₂O-EtOH); ¹H-NMR (DMSO-d₆ + D₂O) δ: 3.64-3.87 (3H, m, 4',5',5''-H), 3.97 (1H, dd, 3'-H, J_{2',3'} = 5.6, J_{3',4'} = 5.9 Hz), 4.31 (1H, dd, 2'-H, J_{1',2'} = 5.9, J_{2',3'} = 5.6 Hz), 5.74 (1H, d, 5-H, J_{5,6} = 7.6 Hz), 6.14 (1H, d, 1'-H, J_{1',2'} = 5.9 Hz), 7.71 (1H, d, 6-H, J_{5,6} = 7.6 Hz).
- 15) mp 192°C (H₂O-MeOH); ¹H-NMR (D₂O) δ: 3.85 (1H, dd, 5'-Ha, J_{4',5'a} = 3.3, J_{5'a,5'b} = 12.8 Hz), 3.99 (1H, dd, 5'-Hb, J_{4',5'b} = 2.2 Hz), 4.19 (1H, ddd, 4'-H, J_{3',4'} = 5.5 Hz), 4.23 (1H, t, 3'-H, J_{2',3'} = J_{3',4'} = 5.5 Hz), 4.48 (1H, t, 2'-H, J_{1',2'} = J_{2',3'} = 5.5 Hz), 6.22 (1H, d, 1'-H), 6.29 (1H, d, 5-H, J_{5,6} = 7.9 Hz), 8.20 (1H, d, 6-H, J_{5,6} = 7.9 Hz).

(Received April 13, 1989)